Patents by Inventor Richard S. Bennett
Richard S. Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11977874Abstract: Methods and systems for monitoring use, determining risk, and pricing insurance policies for a vehicle having one or more autonomous or semi-autonomous operation features are provided. According to certain aspects, an identity of a vehicle operator may be determined and a vehicle operator profile and/or operating data regarding autonomous operation features of the vehicle may be received after the vehicle operator opts into a rewards program and agrees to share their data. Autonomous operation and vehicle operator risk levels associated with operation of the autonomous or semi-autonomous vehicle may be determined. Based upon the risk levels and/or comparison thereof, one or more autonomous operation features may be disengaged. A preparedness level of the vehicle operator to assume or reassume control of operating the vehicle is determined prior to disengagement. If satisfactory, an alert is presented to the vehicle operator prior to disengagement of the autonomous operation features.Type: GrantFiled: January 10, 2022Date of Patent: May 7, 2024Assignee: State Farm Mutual Automobile Insurance CompanyInventors: Brian Mark Fields, Chien Che Huang, Mohamed A. Wazeer, Shawn C. Bennett, Steven C. Cielocha, Ronny S. Bryant, Stephen Kohaus, Terry Quakenbush, Richard A. Novak, Aaron Scott Chan, Craig M. Main, Weixin Wu, Torri Wollenschlager, Carol Marie Csanda, Stacey Gorsuch, Todd Binion
-
Patent number: 11954482Abstract: According to certain aspects, a computer-implemented method for operating an autonomous or semi-autonomous vehicle may be provided. With the customer's permission, an identity of a vehicle operator may be identified and a vehicle operator profile may be retrieved. Operating data regarding autonomous operation features operating the vehicle may be received from vehicle-mounted sensors. When a request to disable an autonomous feature is received, a risk level for the autonomous feature is determined and compared with a driver behavior setting for the autonomous feature stored in the vehicle operator profile. Based upon the risk level comparison, the autonomous vehicle retains control of vehicle or the autonomous feature is disengaged depending upon which is the safer driver—the autonomous vehicle or the vehicle human occupant. As a result, unsafe disengagement of self-driving functionality for autonomous vehicles may be alleviated.Type: GrantFiled: October 11, 2022Date of Patent: April 9, 2024Assignee: State Farm Mutual Automobile Insurance CompanyInventors: Brian Mark Fields, Chien Che Huang, Mohamed A. Wazeer, Shawn C. Bennett, Steven Cielocha, Ronny S. Bryant, Stephen Kohaus, Terry Quakenbush, Richard A. Novak, Aaron Scott Chan, Craig M. Main, Weixin Wu, Torri Wollenschlager, Carol Marie Csanda, Stacey Gorsuch, Todd Binion
-
Publication number: 20200147202Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: ApplicationFiled: January 23, 2020Publication date: May 14, 2020Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human ServicesInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Patent number: 10561724Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: GrantFiled: January 4, 2019Date of Patent: February 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Publication number: 20190117762Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: ApplicationFiled: January 4, 2019Publication date: April 25, 2019Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human ServicesInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Patent number: 10206995Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: GrantFiled: December 21, 2017Date of Patent: February 19, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Publication number: 20180104326Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: ApplicationFiled: December 21, 2017Publication date: April 19, 2018Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human ServicesInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Patent number: 9884104Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACY) infection in a biological sample and infectious chimeric Bunyaviridae.Type: GrantFiled: February 8, 2016Date of Patent: February 6, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Publication number: 20160367657Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACY) infection in a biological sample and infectious chimeric Bunyaviridae.Type: ApplicationFiled: February 8, 2016Publication date: December 22, 2016Inventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Patent number: 9255252Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: GrantFiled: October 2, 2012Date of Patent: February 9, 2016Inventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Publication number: 20140023679Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: ApplicationFiled: October 2, 2012Publication date: January 23, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Patent number: 8298541Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: GrantFiled: March 6, 2008Date of Patent: October 30, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Publication number: 20110200630Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: ApplicationFiled: March 6, 2008Publication date: August 18, 2011Applicant: The Government of the United States of America, as Represented by the Secretary Department of HealthInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy